Furthermore, we report for the first time that piperlongumine inhibited the activation of STAT3 by directly binding to Cys712 near the SH2 domain; piperlongumine had no anti-myeloma effects in cells with mutant STAT3 (C712A). This evidence concerns the gene STAT3 and plasma cell myeloma.